Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer: No Difference, but Not the Same

JAMA. 2017 Jun 20;317(23):2376-2378. doi: 10.1001/jama.2017.6673.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab*
  • Cetuximab*
  • Colorectal Neoplasms / drug therapy
  • Humans
  • Mutation
  • Proto-Oncogene Proteins / genetics
  • ras Proteins / genetics

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Proto-Oncogene Proteins
  • Bevacizumab
  • ras Proteins
  • Cetuximab